Use of quantitative pharmacology tools to improve malaria treatments

References

• Talisuna AO, Bloland P, D’Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev. 2004;17(1):235–254.
   PubMed Web of Science ®Google Scholar
• Wongsrichanalai C, Sibley CH. Fighting drug-resistant Plasmodium falciparum: the challenge of artemisinin resistance. Clin Microbiol Infect. 2013;19(10):908–916.
   PubMed Web of Science ®Google Scholar
• World Health Organization, WHO Global Malaria Programme. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015.
   Google Scholar
• White NJ. Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother. 2013;57(12):5792–5807.
   PubMed Web of Science ®Google Scholar
• Simpson JA, Zaloumis S, DeLivera AM, et al. Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs. Aaps J. 2014;16(5):962–974.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization; 2003.
   Google Scholar
• Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16(4):249–255.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER) [Internet]. Guidance for Industry. Bioanalytical Method Validation; 2013. [cited 2015 Oct]. Available from: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070107.pdf
   Google Scholar
• World Health Organization. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. Geneva: World Health Organization; 2011.
   Google Scholar
• Thomas CG, Ward SA, Edwards G. Selective determination, in plasma, of artemether and its major metabolite, dihydroartemisinin, by high-performance liquid chromatography with ultraviolet detection. J Chromatogr. 1992;583(1):131–136.
   PubMed Web of Science ®Google Scholar
• Batty KT, Davis TM, Thu LT, et al. Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta-dihydroartemisinin in patients with falciparum malaria. J Chromatogr B Biomed Appl. 1996;677(2):345–350.
   PubMed Web of Science ®Google Scholar
• Melendez V, Peggins JO, Brewer TG, et al. Determination of the antimalarial arteether and its deethylated metabolite dihydroartemisinin in plasma by high-performance liquid chromatography with reductive electrochemical detection. J Pharm Sci. 1991;80(2):132–138.
   PubMed Web of Science ®Google Scholar
• Batty KT, Salman S, Moore BR, et al. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study. Antimicrob Agents Chemother. 2012;56(5):2472–2484.
   PubMed Web of Science ®Google Scholar
• Birgersson S, Ericsson T, Blank A, et al. A high-throughput LC-MS/MS assay for quantification of artesunate and its metabolite dihydroartemisinin in human plasma and saliva. Bioanalysis. 2014;6(18):2357–2369.
   PubMed Web of Science ®Google Scholar
• Hilhorst MJ, Hendriks G, De Vries R, et al. A high-performance liquid chromatography-tandem mass spectrometry method for the determination of artemether and dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;965:45–53.
   PubMed Web of Science ®Google Scholar
• Lindegardh N, Hanpithakpong W, Kamanikom B, et al. Quantification of dihydroartemisinin, artesunate and artemisinin in human blood: overcoming the technical challenge of protecting the peroxide bridge. Bioanalysis. 2011;3(14):1613–1624.
   PubMed Web of Science ®Google Scholar
• Debrus B, Lebrun P, Kindenge JM, et al. Innovative high-performance liquid chromatography method development for the screening of 19 antimalarial drugs based on a generic approach, using design of experiments, independent component analysis and design space. J Chromatogr A. 2011;1218(31):5205–5215.
   PubMed Web of Science ®Google Scholar
• Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev. 1984;15(1–2):153–171.
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5(5):445–479.
   PubMedGoogle Scholar
• Aarons L, Ogungbenro K. Optimal design of pharmacokinetic studies. Basic Clin Pharmacol Toxicol. 2010;106(3):250–255.
   PubMed Web of Science ®Google Scholar
• Steimer JL, Mallet A, Golmard JL, et al. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev. 1984;15(1–2):265–292.
   PubMed Web of Science ®Google Scholar
• Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481–504.
   PubMed Web of Science ®Google Scholar
• Holford N. A time to event tutorial for pharmacometricians. CPT Pharmacometrics Syst Pharmacol. 2013;2:e43.
   PubMedGoogle Scholar
• Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34(5):711–726.
   PubMed Web of Science ®Google Scholar
• Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985;228(4703):1049–1055.
   PubMed Web of Science ®Google Scholar
• De Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs. 1996;52(6):818–836.
   PubMed Web of Science ®Google Scholar
• Davis TM, Karunajeewa HA, Ilett KF. Artemisinin-based combination therapies for uncomplicated malaria. Med J Aust. 2005;182(4):181–185.
   PubMed Web of Science ®Google Scholar
• Dondorp A, Nosten F, Stepniewska K, et al., South East Asian Quinine Artesunate Malaria Trial g. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366(9487):717–725.
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647–1657.
   PubMed Web of Science ®Google Scholar
• Qinghaosu Antimalarial Coordinating Research Group. Antimalaria studies on Qinghaosu. Chin Med J (Engl). 1979;92(12):811–816.
   PubMed Web of Science ®Google Scholar
• Edwards G. Measurement of artemisinin and its derivatives in biological fluids. Trans R Soc Trop Med Hyg. 1994;88(Suppl 1):S37–S39.
   PubMed Web of Science ®Google Scholar
• Lindegardh N, Hanpithakpong W, Kamanikom B, et al. Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876(1):54–60.
   PubMed Web of Science ®Google Scholar
• Hien TT, Davis TM, Chuong LV, et al. Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria. Antimicrob Agents Chemother. 2004;48(11):4234–4239.
   PubMed Web of Science ®Google Scholar
• Davis TM, Phuong HL, Ilett KF, et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother. 2001;45(1):181–186.
   PubMed Web of Science ®Google Scholar
• Skinner TS, Manning LS, Johnston WA, et al. In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol. 1996;26(5):519–525.
   PubMed Web of Science ®Google Scholar
• Zaloumis SG, Tarning J, Krishna S, et al. Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. CPT Pharmacometrics Syst Pharmacol. 2014;3:e145.
   PubMedGoogle Scholar
• Salman S, Page-Sharp M, Griffin S, et al. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2011;55(11):5306–5313.
   PubMed Web of Science ®Google Scholar
• Sambol NC, Yan L, Creek DJ, et al. Population pharmacokinetics of piperaquine in young Ugandan children treated with dihydroartemisinin-piperaquine for uncomplicated malaria. Clin Pharmacol Ther. 2015;98(1):87–95.
   PubMed Web of Science ®Google Scholar
• Tarning J, Zongo I, Some FA, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91(3):497–505.
   PubMed Web of Science ®Google Scholar
• WorldWide Antimalarial Resistance Network Lumefantrine PKPDSG. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;13(1):227.
   PubMed Web of Science ®Google Scholar
• Gordi T, Xie R, Huong NV, et al. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. Br J Clin Pharmacol. 2005;59(2):189–198.
   PubMed Web of Science ®Google Scholar
• Salman S, Page-Sharp M, Batty KT, et al. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2012;56(6):3288–3297.
   PubMed Web of Science ®Google Scholar
• White LJ, Flegg JA, Phyo AP, et al. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med. 2015;12(4):e1001823.
   PubMed Web of Science ®Google Scholar
• Bethell D, Se Y, Lon C, et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One. 2011;6(5):e19283.
   PubMed Web of Science ®Google Scholar
• Kay K, Hastings IM. Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs. PLoS Comput Biol. 2013;9(7):e1003151.
   PubMed Web of Science ®Google Scholar
• Brewer TG, Grate SJ, Peggins JO, et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg. 1994;51(3):251–259.
   PubMed Web of Science ®Google Scholar
• Davis TM, Breheny FX, Kendall PA, et al. Severe falciparum malaria with hyperparasitaemia treated with intravenous artesunate. Med J Aust. 1997;166(8):416–418.
   PubMed Web of Science ®Google Scholar
• Hien TT, Turner GD, Mai NT, et al. Neuropathological assessment of artemether-treated severe malaria. Lancet. 2003;362(9380):295–296.
   PubMed Web of Science ®Google Scholar
• Ramos-Martin V, Gonzalez-Martinez C, Mackenzie I, et al. Neuroauditory toxicity of artemisinin combination therapies-have safety concerns been addressed? Am J Trop Med Hyg. 2014;91(1):62–73.
   PubMed Web of Science ®Google Scholar
• Davis TM, Binh TQ, Ilett KF, et al. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother. 2003;47(1):368–370.
   PubMed Web of Science ®Google Scholar
• Manning L, Laman M, Page-Sharp M, et al. Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether. Antimicrob Agents Chemother. 2011;55(11):5027–5033.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Assessment of the safety of artemisinin compounds in pregnancy. Geneva: World Health Organisation; 2006.
   Google Scholar
• Davis TME, Mueller I, Rogerson SJ. Prevention and treatment of malaria in pregnancy. Future Microbiology. 2010;5(10):1599–1613.
   PubMed Web of Science ®Google Scholar
• Benjamin JM, Moore BR, Salman S, et al. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women. Antimicrob Agents Chemother. 2015;59(7):4260–4271.
   PubMed Web of Science ®Google Scholar
• Tarning J, Rijken MJ, McGready R, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother. 2012;56(4):1997–2007.
   PubMed Web of Science ®Google Scholar
• Jansen FH, Jansen-Luts A, Ameye C, et al. Is artesunate or its active metabolite dihydroartemisinin being excreted in the milk of lactating mothers? Am J Trop Med Hyg. 2006;75(5 Suppl):158 (Abstract 543).
   PubMed Web of Science ®Google Scholar
• D’Alessandro U, Ubben D, Hamed K, et al. Malaria in infants aged less than six months - is it an area of unmet medical need? Malar J. 2012;11:400.
   PubMed Web of Science ®Google Scholar
• Larru B, Molyneux E, Ter Kuile FO, et al. Malaria in infants below six months of age: retrospective surveillance of hospital admission records in Blantyre, Malawi. Malar J. 2009;8:310.
   PubMed Web of Science ®Google Scholar
• Milsap RL, Jusko WJ. Pharmacokinetics in the infant. Environ Health Perspect. 1994;102(Suppl 11):107–110.
   PubMed Web of Science ®Google Scholar
• Kiang TK, Wilby KJ, Ensom MH. Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals. Clin Pharmacokinet. 2014;53(2):141–153.
   PubMed Web of Science ®Google Scholar
• Van Geertruyden JP. Interactions between malaria and human immunodeficiency virus anno 2014. Clin Microbiol Infect. 2014;20(4):278–285.
   PubMed Web of Science ®Google Scholar
• Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother. 2006;50(2):639–648.
   PubMed Web of Science ®Google Scholar
• Achan J, Kakuru A, Ikilezi G, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012;367(22):2110–2118.
   PubMed Web of Science ®Google Scholar
• Gomes MF, Faiz MA, Gyapong JO, et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet. 2009;373(9663):557–566.
   PubMed Web of Science ®Google Scholar
• Karunajeewa HA, Manning L, Mueller I, et al. Rectal administration of artemisinin derivatives for the treatment of malaria. Jama. 2007;297(21):2381–2390.
   PubMed Web of Science ®Google Scholar
• Salman S, Bendel D, Lee TC, et al. Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria. Antimicrob Agents Chemother. 2015;59(6):3208–3215.
   PubMed Web of Science ®Google Scholar
• Bendel D, Rulisa S, Ansah P, et al. Efficacy of a novel sublingual spray formulation of artemether in African children with falciparum malaria. Antimicrob Agents Chemother. 2015;59(11):6930–6938.
   Web of Science ®Google Scholar
• Chen PQ, Li GQ, Guo XB, et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J (Engl). 1994;107(9):709–711.
   PubMed Web of Science ®Google Scholar
• Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24(2):377–410.
   PubMed Web of Science ®Google Scholar
• Karl S, Laman M, Moore BR, et al. Gametocyte clearance kinetics determined by quantitative magnetic fractionation in Melanesian children with uncomplicated malaria treated with artemisinin combination therapy. Antimicrob Agents Chemother. 2015;59(8):4489–4496.
   PubMed Web of Science ®Google Scholar
• Makanga M. A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmission. Malar J. 2014;13:291.
   PubMed Web of Science ®Google Scholar
• Delves MJ, Ruecker A, Straschil U, et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother. 2013;57(7):3268–3274.
   PubMed Web of Science ®Google Scholar
• White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet. 1999;353(9168):1965–1967.
   PubMed Web of Science ®Google Scholar
• Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363(9402):9–17.
   PubMed Web of Science ®Google Scholar
• Davis TM, Hung TY, Sim IK, et al. Piperaquine: a resurgent antimalarial drug. Drugs. 2005;65(1):75–87.
   PubMed Web of Science ®Google Scholar
• Batty KT, Moore BR, Stirling V, et al. Investigation of reproductive toxicity of piperaquine in mice. Reprod Toxicol. 2010;29(2):206–213.
   PubMed Web of Science ®Google Scholar
• Karunajeewa HA, Mueller I, Senn M, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359(24):2545–2557.
   PubMed Web of Science ®Google Scholar
• Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007;369(9563):757–765.
   PubMed Web of Science ®Google Scholar
• Aweeka FT, German PI. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet. 2008;47(2):91–102.
   PubMed Web of Science ®Google Scholar
• Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol. 1998;46(6):553–561.
   PubMed Web of Science ®Google Scholar
• Ramharter M, Kurth F, Schreier AC, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis. 2008;198(6):911–919.
   PubMed Web of Science ®Google Scholar
• Denis MB, Tsuyuoka R, Lim P, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006;11(12):1800–1807.
   PubMed Web of Science ®Google Scholar
• Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15(6):683–691.
   PubMed Web of Science ®Google Scholar
• Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet. 2010;375(9724):1457–1467.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report. Pyramax (pyronaridine tetraphosphate/artesunate). [Internet] Procedure No.: EMEA/H/W/002319; 2012. [cited 2015 Oct]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500129290.pdf
   Google Scholar
• Sagara I, Beavogui AH, Zongo I, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2015. doi:10.1016/S1473-3099(15)00318-7. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Wang JY, Cao WC, Shan CQ, et al. Naphthoquine phosphate and its combination with artemisinine. Acta Trop. 2004;89(3):375–381.
   PubMed Web of Science ®Google Scholar
• Benjamin J, Moore B, Lee ST, et al. Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Antimicrob Agents Chemother. 2012;56(5):2465–2471.
   PubMed Web of Science ®Google Scholar
• Laman M, Moore BR, Benjamin JM, et al. Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial. PLoS Med. 2014;11(12):e1001773.
   PubMed Web of Science ®Google Scholar
• Hastings IM, Hodel EM. Pharmacological considerations in the design of anti-malarial drug combination therapies - is matching half-lives enough? Malar J. 2014;13:62.
   PubMed Web of Science ®Google Scholar
• Hung TY, Davis TM, Ilett KF. Measurement of piperaquine in plasma by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;791(1–2):93–101.
   PubMed Web of Science ®Google Scholar
• Karunajeewa HA, Ilett KF, Mueller I, et al. Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother. 2008;52(1):237–243.
   PubMed Web of Science ®Google Scholar
• Laman M, Benjamin JM, Moore BR, et al. Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: a six months post-treatment follow-up study. Malar J. 2015;14:121.
   PubMed Web of Science ®Google Scholar
• Visser BJ, Wieten RW, Kroon D, et al. Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J. 2014;13:463.
   PubMed Web of Science ®Google Scholar
• Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health Organ. 2011;89(1):46–53.
   PubMed Web of Science ®Google Scholar
• Kay K, Hodel EM, Hastings IM. Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials. Antimicrob Agents Chemother. 2014;58(10):5643–5649.
   PubMed Web of Science ®Google Scholar
• Jager NG, Rosing H, Schellens JH, et al. Procedures and practices for the validation of bioanalytical methods using dried blood spots: a review. Bioanalysis. 2014;6(18):2481–2514.
   PubMed Web of Science ®Google Scholar
• Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci. 2002;357(1420):505–519.
   PubMed Web of Science ®Google Scholar
• Koleala T, Karl S, Laman M, et al. Temporal changes in Plasmodium falciparum anti-malarial drug sensitivity in vitro and resistance-associated genetic mutations in isolates from Papua New Guinea. Malar J. 2015;14:37.
   PubMed Web of Science ®Google Scholar
• Pascual A, Parola P, Benoit-Vical F, et al. Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar J. 2012;11:45.
   PubMed Web of Science ®Google Scholar
• Moore BR, Salman S, Benjamin J, et al. Pharmacokinetics of piperaquine transfer into the breast milk of Melanesian mothers. Antimicrob Agents Chemother. 2015;59(7):4272–4278.
   PubMed Web of Science ®Google Scholar
• White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7(8):549–558.
   PubMed Web of Science ®Google Scholar
• Bouchaud O, Imbert P, Touze JE, et al. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Malar J. 2009;8:289.
   PubMed Web of Science ®Google Scholar
• Van Vugt M, Ezzet F, Nosten F, et al. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg. 1999;61(6):964–967.
   PubMed Web of Science ®Google Scholar
• Sim IK, Davis TM, Ilett KF. Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother. 2005;49(6):2407–2411.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Eurartesim: annex I. Summary of product characteristics; 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001199/human_med_001450.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Manning J, Vanachayangkul P, Lon C, et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother. 2014;58(10):6056–6067.
   PubMed Web of Science ®Google Scholar
• Borsini F, Crumb W, Pace S, et al. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother. 2012;56(6):3261–3270.
   PubMed Web of Science ®Google Scholar
• Moore BR, Benjamin JM, Salman S, et al. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2014;58(10):5784–5794.
   PubMed Web of Science ®Google Scholar
• Van Dorn CS, Johnson JN, Taggart NW, et al. QTc values among children and adolescents presenting to the emergency department. Pediatrics. 2011;128(6):e1395–e1401.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Day NP, Ly VC, et al. Post-malaria neurological syndrome. Lancet. 1996;348(9032):917–921.
   PubMed Web of Science ®Google Scholar
• Isba R, Zani B, Gathu M, et al. Artemisinin-naphthoquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2015;2:CD011547.
   PubMed Web of Science ®Google Scholar
• Trinkley KE, Page RL 2nd, Lien H, et al. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013;29(12):1719–1726.
   PubMed Web of Science ®Google Scholar
• Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol. 2011;7(9):1153–1167.
   PubMed Web of Science ®Google Scholar
• Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol. 1995;76(10):675–678.
   PubMed Web of Science ®Google Scholar
• Smalley ME, Sinden RE. Plasmodium falciparum gametocytes: their longevity and infectivity. Parasitology. 1977;74(1):1–8.
   PubMed Web of Science ®Google Scholar
• Stepniewska K, Taylor WR, Mayxay M, et al. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother. 2004;48(11):4271–4280.
   PubMed Web of Science ®Google Scholar
• Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39(9):1336–1345.
   PubMed Web of Science ®Google Scholar
• Crockett M, Kain KC. Tafenoquine: a promising new antimalarial agent. Expert Opin Investig Drugs. 2007;16(5):705–715.
   PubMed Web of Science ®Google Scholar
• John GK, Douglas NM, Von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280.
   PubMed Web of Science ®Google Scholar
• Ebringer A, Heathcote G, Baker J, et al. Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects. Trans R Soc Trop Med Hyg. 2011;105(10):568–573.
   PubMed Web of Science ®Google Scholar
• Moore BR, Salman S, Benjamin J, et al. Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. Antimicrob Agents Chemother. 2014;58(1):432–439.
   PubMed Web of Science ®Google Scholar
• Bennett JW, Pybus BS, Yadava A, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369(14):1381–1382.
   PubMed Web of Science ®Google Scholar
• Potter BM, Xie LH, Vuong C, et al. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59(4):2380–2387.
   PubMed Web of Science ®Google Scholar
• Tenero D, Green JA, Goyal N. Exposure-response analyses for tafenoquine after administration to patients with plasmodium vivax malaria. Antimicrob Agents Chemother. 2015;59(10):6188–6194.
   PubMed Web of Science ®Google Scholar
• Rajapakse S, Rodrigo C, Fernando SD. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2015;4:CD010458.
   PubMedGoogle Scholar
• Marcsisin SR, Sousa JC, Reichard GA, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014;13:2.
   PubMed Web of Science ®Google Scholar
• Leary KJ, Riel MA, Roy MJ, et al. A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers. Am J Trop Med Hyg. 2009;81(2):356–362.
   PubMed Web of Science ®Google Scholar
• Held J, Jeyaraj S, Kreidenweiss A. Antimalarial compounds in Phase II clinical development. Expert Opin Investig Drugs. 2015;24(3):363–382.
   PubMed Web of Science ®Google Scholar
• Rottmann M, McNamara C, Yeung BK, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010;329(5996):1175–1180.
   PubMed Web of Science ®Google Scholar
• Zhang R, Suwanarusk R, Malleret B, et al. A basis for rapid clearance of circulating ring-stage malaria parasites by the spiroindolone KAE609. J Infect Dis. 2015;213(1):100–104.
   Google Scholar
• Leong FJ, Li R, Jain JP, et al. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014;58(10):6209–6214.
   PubMed Web of Science ®Google Scholar
• White NJ, Pukrittayakamee S, Phyo AP, et al. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med. 2014;371(5):403–410.
   PubMed Web of Science ®Google Scholar